Bullous pemphigoid outcome is associated with CXCL10-induced matrix metalloproteinase 9 secretion from monocytes and neutrophils but not lymphocytes.
Fiche publication
Date publication
mars 2017
Journal
The Journal of allergy and clinical immunology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ANTONICELLI Franck, Pr LE NAOUR Richard
Tous les auteurs :
Riani M, Le Jan S, Plée J, Durlach A, Le Naour R, Haegeman G, Bernard P, Antonicelli F
Lien Pubmed
Résumé
The outcome of bullous pemphigoid (BP), the most frequent autoimmune skin-blistering disease, involves matrix metalloproteinase 9 (MMP-9), IL-17, and IL-23 release from infiltrated inflammatory cells. The chemokine CXCL10 has been associated with several autoimmune diseases, but its participation in BP pathophysiology still needs to be clarified.
Mots clés
Bullous pemphigoid, CXCL10, autoimmunity, compound A, inflammation, selective glucocorticoid receptor activator
Référence
J. Allergy Clin. Immunol.. 2017 Mar;139(3):863-872.e3